New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus.

This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  

New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus.

This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  

New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before. The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE). Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus. This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before. The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE). Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus.

This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  

New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus.

This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  

New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before. The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE). Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.

New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic  management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the role of bariatric as a management tool for diabetes is covered as well as consideration of the organisation of diabetes care with a community focus. This indispensable pocketbook details the newer treatments and offers a comparison with more traditional agents including sulphonyureas, glitazones and insulin. The pros and cons of traditional therapies are discussed as well as the epidemiology and pathogenesis of type 2 diabetes, helping to give the reader a better understanding of the disease area and its management.  New Mechanisms in Glucose Control is essential reading for health professionals working in primary or secondary care and involved in treating diabetic patients.

In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before. The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE). Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.